title: [Survival Benefit with Consolidative Radiotherapy in Early-Stage Diffuse Large B‑Cell Lymphoma patients].
authors.affiliation: Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Deutschland.
authors.forename: Khaled
authors.initials: K
authors.lastname: Elsayad
authors.affiliation: Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Deutschland. hans.eich@ukmuenster.de.
authors.forename: Hans Theodor
authors.initials: HT
authors.lastname: Eich
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage; D059248:Chemoradiotherapy / Q000379:methods / Q000401:mortality*; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis / Q000401:mortality* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000401:mortality* / Q000517:prevention & control; D015995:Prevalence; D011879:Radiotherapy Dosage; D012074:Remission Induction / Q000379:methods; D012189:Retrospective Studies; D018570:Risk Assessment; D000069283:Rituximab / Q000008:administration & dosage; D013274:Stomach Neoplasms / Q000175:diagnosis / Q000401:mortality* / Q000628:therapy*; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D000069283:Rituximab